c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia

Leukemia

Volumn 22, Issue 10, 2008, Pages 1899-1908

  Lagadinou, E D ^a   Ziros, P G ^a   Tsopra, O A ^a   Dimas, K ^b   Kokkinou, D ^a   Thanopoulou, E ^a   Karakantza, M ^a   Pantazis, P ^b   Spyridonidis, A ^a   Zoumbos, N C ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; JANUS KINASE 1; STRESS ACTIVATED PROTEIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 54049101586     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.192     Document Type: Article

References (39)

1. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368 1894-1907.
2. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87: 1997-2004.
3. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995). J Clin Oncol 2004; 22: 1078-1086.
4. Matsouka P, Pagoni M, Zikos P, Giannakoulas N, Apostolidis I, Asprogeraka T et al. Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology. Ann Hematol 2006; 85: 250-256.
5. Schimmer AD, Hedley DW, Penn LZ, Minden MD. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: A translational view. Blood 2001; 98: 3541-3553.
6. Lauria F, Raspadori D, Rondelli D, Ventura MA, Fiacchini M, Visani G et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997; 11: 2075-2078.
7. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103: 239-252.
8. Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 2001; 4: 253-267.
9. Herr I, Debatin KM. Cellular stress response and apoptosis in cancer therapy. Blood 2001; 98: 2603-2614.
10. Cripe LD, Gelfanov VM, Smith EA, Spigel DR, Phillips CA, Gabig TG et al. Role for c-jun N-terminal kinase in treatment-refractory acute myeloid leukemia (AML): Signaling to multidrug-efflux and hyperproliferation. Leukemia 2002; 16: 799-812.
11. Gregorj C, Ricciardi MR, Petrucci MT, Scerpa MC, De Cave F, Fazi P et al. ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood 2007; 109: 5473-5476.
12. Nolan G. Deeper insights into hematological disorders via single-cell phospho-signaling analysis. Hematology (Am Soc Hematol Educ Program) 2006; 509: 123-127.
13. Mansat-deMas V, Bezombes C, Quillet-Mary A, Bettaieb A, D'Orgeix AD, Laurent G et al. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol 1999; 56: 867-874.
14. Laurent G, Jaffrezou JP. Signaling pathways activated by daunorubicin. Blood 2001; 98: 913-924.
15. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 2004; 112: 974-985.
16. Li F, Meng L, Xing H, Zhou J, Wang S, Huang L et al. Essential role of c-Jun-NH2-terminal kinase on synergy induction of apoptosis by TRAIL plus ADM in ADM resistant MCF-7/ADM cells. Apoptosis 2006; 11: 1239-1246.
17. Kang CD, Ahn BK, Jeong CS, Kim KW, Lee HJ, Yoo SD et al. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein. Exp Cell Res 2000; 256: 300-307.
18. Li F, Meng L, Zhou J, Xing H, Wang S, Xu G et al. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: A role of c-Jun NH2-terminal kinase 1. Biochem Biophys Res Commun 2005; 335: 1070-1077.
19. Pantazis P, Dejesus A, Early J, Rodriguez R, Chatterjee D, Han Z et al. Development of human leukemia U-937 cell sublines resistant to doxorubicin: Induction of differentiation and altered sensitivities to topoisomerase-directed drugs. Anticancer Res 1995; 15 (5B): 1873-1881.
20. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE. Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vivo experiments and treatment protocols. Cancer Res 1983; 43: 3417-3421.
21. Ziros PG, Gil AP, Georgakopoulos T, Habeos I, Kletsas D, Basdra EK et al. The bone-specific transcriptional regulator Cbfa1 is a target of mechanical signals in osteoblastic cells. J Biol Chem 2002; 277 23934-23941.
22. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F et al Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 85: 2147-2153.
23. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science (New York, NY) 1994; 265: 966-970.
24. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368-2373.
25. Legr,and O, Simonin G, Perrot JY, Zittoun R, Marie JP. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 1998; 91: 4480-4488.
26. Tournier C, Hess P, Yang DD, Xu J, Turner TK, Nimnual A et al. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000; 288: 870-874.
27. Zhou J, Liu M, Aneja R, Chandra R, Lage H, Joshi HC. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 2006; 66: 445-452.
28. Hatle KM, Neveu W, Dienz O, Rymarchyk S, Barrantes R, Hale S et al Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression. Mol Cell Biol 2007; 27 2952-2966.
29. Dasmahapatra G, Rahmani M, Dent P, Grant S. The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism. Blood 2006; 107: 232-240.
30. Dai Y, Rahmani M, Pei XY, Khanna P, Han SI, Mitchell C et al. Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/ JNK. Blood 2005; 105: 1706-1716.
31. Gao N, Rahmani M, Shi X, Dent P, Grant S. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress. Blood 2006; 107: 241-249.
32. Davison K, Mann KK, Waxman S, Miller Jr WH. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004; 103: 3496-3502.
33. Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 2006; 107: 2517-2524.
34. Wang T, Arifoglu P, Ronai Z, Tew KD. Glutathione S-transferase P1-1(GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 2001; 276: 20999-21003.
35. Wang Z, Xu J, Zhou JY, Liu Y, Wu GS. Mitogen-Activated Protein Kinase Phosphatase-1 is required for Cisplatin Resistance. Cancer Res 2006; 66: 8870-8877.
36. Beere HM. Death versus survival: Functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest 2005; 115: 2633-2639.
37. Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001; 414: 313-317.
38. Gore S. ROS' n' roll: A bunch of JNK? Blood 2006; 107: 9-10.
39. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I et al. The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism. Leukemia 2008; 22: 1106-1116.